ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  05/20 04:04:08 pm EDT
298.85 USD   +4.39%
05/20Eli Lilly, Incyte Say EMA Committee Recommends Approval of Alopecia Areata Drug Candidate
MT
05/20Lilly and Incyte's Olumiant Gets CHMP Recommendation in Alopecia Areata
DJ
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Berenberg Bank Adjusts Eli Lilly and Company PT to $305 From $270, Maintains Buy Rating

12/20/2021 | 08:22am EDT


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
05/20Eli Lilly, Incyte Say EMA Committee Recommends Approval of Alopecia Areata Drug Candida..
MT
05/20Lilly and Incyte's Olumiant Gets CHMP Recommendation in Alopecia Areata
DJ
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
05/16Eli Lilly Says FDA Approves Mounjaro Injection to Control Diabetes; Shares Rise
MT
05/13FDA Approves Lilly's Mounjaro (Tirzepatide) Injection, the First and Only GIP and GLP-1..
CI
05/13FDA Approves Eli Lilly's Novel, Dual-Targeted Treatment for Type 2 Diabetes
MT
05/13Berenberg Bank Adjusts Eli Lilly's Price Target to $345 From $305, Maintains Buy Rating
MT
05/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/11Eli Lilly and Incyte Say Olumiant, Their COVID-19 Treatment for Hospitalized Adults, Ap..
MT
05/11FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients
DJ
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 29 036 M - -
Net income 2022 6 997 M - -
Net Debt 2022 9 221 M - -
P/E ratio 2022 39,4x
Yield 2022 1,26%
Capitalization 269 B 269 B -
EV / Sales 2022 9,58x
EV / Sales 2023 9,07x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 298,85 $
Average target price 313,14 $
Spread / Average Target 4,78%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY8.19%269 013
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099